Tom Hunter has backed Chris Evans’s venture capital company Merlin Biosciences, to take on larger deals beyond its customary start-up market. The fundraising comes as Evans is under investigation by Scotland Yard for his involvement in the cash-for-honours inquiry.
AllianzGI leaves door open for reversal of PE pullback
5 November 2026 · 2 mins read
How Schroders’ $30bn PE funds platform is growing its CV and co-invest allocations
5 November 2026 · 4 mins read
Side Letter: Johns, jitters, judgment calls
4 November 2026 · 5 mins read
Rothschild & Co’s private client unit seeks to rebalance PE portfolio
4 November 2026 · 2 mins read
Weil wind-down: How fund mandates will be affected
4 November 2026 · 4 mins read
Side Letter: Blended buyouts
3 November 2026 · 3 mins read
Blackstone’s Gray: Some AI investments 'will go awry'
3 November 2026 · 3 mins read
